Valion Bio (NASDAQ: VBIO) has provided an update for its Entolimod program—including continued engagement with U.S. government agencies and allied nations on Acute Radiation Syndrome (ARS) preparedness, a demonstrated 200-fold manufacturing scale-up through its wholly owned subsidiary Velocity Bioworks, and planned expansion into innovative oncology supportive care.
According to Valion, these developments reflect the evolution from a single product candidate into an integrated biotechnology platform. Taken together, these initiatives have significantly strengthened the company’s ability to pursue multiple avenues of near-, mid- and long-term value creation.
In a statement, Michael K. Handley, CEO of Valion, commented, “Over the past year, our focus has extended beyond advancing a single product candidate. We have been building the regulatory, government, clinical and manufacturing capabilities needed to support the long-term development of the Entolimod platform.”
He added, “Today, Valion Bio has a biodefense program advancing under the FDA Animal Rule, active engagement with U.S. and allied-government stakeholders, company-owned domestic manufacturing and a defined path toward innovating important potential applications in oncology supportive care.”
Valion continues to engage with BARDA, NIAID, AFRRI and the DoW regarding potential non-dilutive development support and future strategic national stockpile opportunities. These discussions remain ongoing, and while no funding, procurement or stockpiling agreement has been executed, Valion believes these conversations have been productive and evidence a potentially strong collaboration.
